SCHEMBL19344281

SCHEMBL19344281

CC1(C)O[C@@H]2[C@H](O1)[C@@H](CN1CCC(F)(F)C[C@H]1CN1CCCC1)O[C@H]2c1ccc2c(N)ncnn12

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ POLRMT O00411 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19344076 0.89 — —
SCHEMBL22434993 0.89 DOT1L (0.30) —
SCHEMBL19344170 0.86 POLRMT (0.30) POLRMT
SCHEMBL19343942 0.86 POLRMT (0.32) POLRMT
SCHEMBL19344160 0.86 POLRMT (0.35) POLRMT
SCHEMBL19344169 0.86 POLRMT (0.35) POLRMT
SCHEMBL19343950 0.84 — —
SCHEMBL19344280 0.82 CSNK2A2 (0.30) POLRMT
SCHEMBL19343949 0.81 CSNK2A2 (0.32) —
SCHEMBL19343972 0.81 DOT1L (0.31) POLRMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 — — US disclosed
WO-2017153186-A1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 POLRMT 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback